Prostate Cancer | Clinical

Olaparib Treatment Leads to Significant Survival Improvement in Patients with mCRPC

December 04, 2020

A significantly longer overall survival was observed with olaparib in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM, compared with those who received enzalutamide or abiraterone plus prednisone, according to research presented at the 21st Annual Meeting of the Society of Urologic Oncology.

Understanding the Various Biomarker Settings for Metastatic Prostate Cancer

December 04, 2020

In a presentation during the 21st Annual Meeting of the Society of Urologic Oncology, Kara N. Maxwell, MD, PhD, expanded upon the available biomarkers for use in prostate cancer and how they can be applied at various points and for guiding toward which treatments can improve care of patients with prostate cancer.

Enzalutamide Shows PFS Benefit Across Subgroups of nmCRPC

December 03, 2020

Enzalutamide achieved both an improvement in progression-free survival and an increase in time to PSA progression compared with bicalutamide as treatment of patients with nonmetastatic castration-resistant prostate cancer.

Exploring PSMA Therapies in Prostate Cancer

December 03, 2020

Declan Murphy, MD, discusses the current interest in using PSMA, following the FDA’s approval of Gallium 68 PSMA-11, which marks the first ever drug for PET imaging of PSMA-positive lesions in men with prostate cancer.